Syntab Therapeutics is a German biotech company that has developed an immuno-oncology therapy which employs the innate immune system to kill cancer cells highly effectively and to provide long-lasting anti-cancer benefits to patients. Syntab’s technology platform offers a new path in the cancer therapy space and is expected to exhibit excellent selectivity for a range of cancer-relevant targets. The company established a lean management for its development in tight collaboration with a few selective and excellent academic partners as the group of Prof. Christian Becker in Vienna and Aachen University for preclinical studies. The company has its registered office in Würselen close to Aachen.